BRPI0510657A - tratamento com cisplatina e com um inibidor de egfr - Google Patents

tratamento com cisplatina e com um inibidor de egfr

Info

Publication number
BRPI0510657A
BRPI0510657A BRPI0510657-5A BRPI0510657A BRPI0510657A BR PI0510657 A BRPI0510657 A BR PI0510657A BR PI0510657 A BRPI0510657 A BR PI0510657A BR PI0510657 A BRPI0510657 A BR PI0510657A
Authority
BR
Brazil
Prior art keywords
treatment
cisplatin
kinase inhibitor
egfr kinase
egfr
Prior art date
Application number
BRPI0510657-5A
Other languages
English (en)
Inventor
Brian Higgins
Kenneth Kolinsky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0510657A publication Critical patent/BRPI0510657A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TRATAMENTO COM CISPLATINA E COM UM INIBIDOR DE EGFR A presente invenção fornece um processo para a fabricação de um medicamento para o tratamento de tumores ou de metástases de tumor, caracterizado pelo fato de que eficaz de um inibidor de EGFR quinase é usada uma quantidade terapeuticamente e cispiatina, com ou sem agentes adicionais ou tratamentos, tais como outros fármacos anticâncer ou terapia com radiação. A invenção também abrange uma composição farmacêutica que consiste em uma combinação de um inibidor de EGFR quinase e cispiatina em combinação com um veículo farmaceuticamente aceitável. Um exemplo preferido de um inibidor de EGFR quinase que pode ser usado na prática desta invenção é o composto erlotinib HCI (também conhecido como Tarceva<32>).
BRPI0510657-5A 2004-06-03 2005-05-27 tratamento com cisplatina e com um inibidor de egfr BRPI0510657A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57679004P 2004-06-03 2004-06-03
PCT/EP2005/005737 WO2005117916A1 (en) 2004-06-03 2005-05-27 Treatment with cisplatin and an egfr-inhibitor

Publications (1)

Publication Number Publication Date
BRPI0510657A true BRPI0510657A (pt) 2007-12-04

Family

ID=34969379

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510657-5A BRPI0510657A (pt) 2004-06-03 2005-05-27 tratamento com cisplatina e com um inibidor de egfr

Country Status (14)

Country Link
US (1) US7951405B2 (pt)
EP (1) EP1758601A1 (pt)
JP (1) JP2008501654A (pt)
CN (1) CN1968706A (pt)
AU (1) AU2005249206A1 (pt)
BR (1) BRPI0510657A (pt)
CA (1) CA2567852A1 (pt)
IL (1) IL179533A0 (pt)
MX (1) MXPA06014002A (pt)
NO (1) NO20066054L (pt)
NZ (1) NZ551431A (pt)
RU (1) RU2006146612A (pt)
WO (1) WO2005117916A1 (pt)
ZA (1) ZA200610053B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
RU2006146625A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение иринотеканом (срт-11) и ингибитором рецептора эпидермального фактора роста (egfr)
US20070141066A1 (en) * 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
US20080299113A1 (en) * 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
EP2250173A1 (en) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
US20100035853A1 (en) * 2008-08-07 2010-02-11 Hyogo College Of Medicine Method for preventing or treating cisplatin-induced nephrotoxicity
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
KR101556726B1 (ko) * 2010-02-24 2015-10-02 바이오디식스, 인크. 질량스펙트럼 분석을 이용한 치료제 투여를 위한 암 환자 선별
US9717792B2 (en) 2012-02-02 2017-08-01 The University Of British Columbia Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates
US8718996B2 (en) * 2012-07-05 2014-05-06 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
WO2014018953A1 (en) * 2012-07-27 2014-01-30 Indiana University Resarch And Technology Corporation Inauhzin analogues that induce p53, inhibit cell growth, and have antitumor activity
RU2559130C1 (ru) * 2014-04-25 2015-08-10 Федеральное государственное бюджетное учреждение "Медицинский радиологический научный центр" Министерства здравоохранения Российской Федерации (ФГБУ МРНЦ Минздрава России) Способ лечения неоперабельного немелкоклеточного рака легкого
CA2968680A1 (en) * 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
CN112661739A (zh) * 2020-12-30 2021-04-16 福建省中科生物股份有限公司 一种萜酚类化合物及其与顺铂联用在抗肿瘤医药上的用途
EP4329778A4 (en) * 2021-04-26 2025-02-19 Crititech, Inc. CISPLATIN PARTICLES AND THEIR USES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
TW587938B (en) 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
AU4079999A (en) 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EE200100603A (et) 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
ES2272305T3 (es) 1999-08-12 2007-05-01 Wyeth Holdings Corporation Composicion de contine un nsaid y un inhibidor de efgr cinasa para el tratamiento o la inhibicion de los polipos de colon y del cancer colorrectal.
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
WO2002039121A2 (en) 2000-11-03 2002-05-16 Board Of Regents, The University Of Texas System Methods for detecting the efficacy of anticancer treatments
AU2002239486A1 (en) 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
AU2002315306B2 (en) 2001-05-08 2007-05-17 Merck Patent Gmbh Combination therapy using anti-EGFR antibodies and anti-hormonal agents
CA2482591A1 (en) 2002-04-16 2003-10-30 Astrazeneca Ab Combination therapy for the treatment of cancer
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
KR20060054412A (ko) * 2003-08-01 2006-05-22 와이어쓰 홀딩스 코포레이션 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도

Also Published As

Publication number Publication date
EP1758601A1 (en) 2007-03-07
AU2005249206A1 (en) 2005-12-15
CN1968706A (zh) 2007-05-23
JP2008501654A (ja) 2008-01-24
IL179533A0 (en) 2007-05-15
WO2005117916A1 (en) 2005-12-15
MXPA06014002A (es) 2007-02-08
RU2006146612A (ru) 2008-07-20
CA2567852A1 (en) 2005-12-15
US20050271747A1 (en) 2005-12-08
NO20066054L (no) 2007-01-25
NZ551431A (en) 2010-04-30
ZA200610053B (en) 2008-02-27
US7951405B2 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
BR0116575A (pt) Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
WO2007106503A3 (en) Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
BRPI0622054B8 (pt) composto e composição farmacêutica
ECSP055911A (es) Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
BR112014016163A8 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
PT1951730E (pt) Derivados de pirimidina ligados a heteroalquilo
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer
NO20066054L (no) behandling med cisplatin og en EGFR-inhibitor
BR0313470A (pt) Combinações terapêuticas de inibidores erbb quinase e terapias antineoplásicas
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
BRPI0409926A (pt) saposina c-dops: um agente antitumor
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
BR112022026386A2 (pt) Inibidor de fgfr e mutação, método de preparação do mesmo e uso farmacêutico do mesmo
BRPI0511780A (pt) tratamento com oxoliplatina e um inibidor de egrf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.